Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc., a Delaware corporation, on August 3, 2018, reporting events occurring on July 31, 2018. The registrant is identified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
On July 31, 2018, the Company appointed Frank Morich as a new member of its Board of Directors. Dr. Morich brings over 35 years of biopharmaceutical industry experience, including prior roles as Chief Commercial Officer at Takeda Pharmaceutical and Chairman of the Board of Bayer Healthcare AG.
Compensation and Governance Details
- Annual Compensation: Dr. Morich will receive an annual cash retainer of $35,000 and an annual stock option award covering 8,000 shares of common stock.
- Initial Grant: Upon appointment, he received a stock option award covering 50,000 shares of common stock.
- Vesting Schedule: The initial 50,000-share award vests in eight equal semi-annual installments.
Outlook and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on financial performance, or specific risk factors beyond the standard disclosure of the director appointment.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 50,000 initial stock options granted to Dr. Morich.
- Review the Company's full Director Compensation Policy to understand total potential equity exposure.
- Confirm Dr. Morich's independence status and any potential conflicts of interest given his current consulting roles and past board memberships.
- Check subsequent filings for any changes to the Board composition or executive leadership.